Dermata Therapeutics Stock Investor Sentiment
| DRMA Stock | USD 1.18 0.04 3.28% |
About 61% of Dermata Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Dermata Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Dermata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Dermata Therapeutics stock news signals to limit their universe of possible portfolio assets.
Dermata |
Dermata Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Dermata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Dermata Therapeutics that are available to investors today. That information is available publicly through Dermata media outlets and privately through word of mouth or via Dermata internal channels. However, regardless of the origin, that massive amount of Dermata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Dermata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Dermata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Dermata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Dermata Therapeutics alpha.
Dermata Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Scott Kathleen D. of 5000 shares of Dermata Therapeutics at 1.38 subject to Rule 16b-3 | 01/13/2025 |
2 | Acquisition by David Hale of 78741 shares of Dermata Therapeutics at 1.27 subject to Rule 16b-3 | 01/21/2025 |
3 | Dermata Therapeutics Announces 2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules | 01/22/2025 |
4 | Dermata Therapeutics Announces Closing of 2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules | 01/23/2025 |
5 | Dermata Therapeutics files to sell 1.94M shares of common stock for holders | 01/30/2025 |
6 | Acquisition by Fisher Mary of 8602 shares of Dermata Therapeutics subject to Rule 16b-3 | 02/26/2025 |
7 | Ensysce Biosciences Stock Price, Quotes and Forecasts NASDAQENSC - Benzinga | 02/28/2025 |
8 | Acquisition by Van Hoose Kyri K. of 30000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3 | 03/07/2025 |
9 | Acquisition by Gerald Proehl of 45000 shares of Dermata Therapeutics at 1.38 subject to Rule 16b-3 | 03/18/2025 |
Complementary Tools for Dermata Stock analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |